Exhibit 99.1

Image of Ebola viruses exiting host cells - Courtesy of NIAID 1

The following presentation may contain predictions, estimates, and other forward looking statements that involve risks and uncertainties, including whether and when our products are successfully developed and introduced ; market acceptance of the Aethlon Hemopurifier® and other product offerings ; regulatory delays, manufacturing delays, and other risks detailed in our SEC filings, which are accessible at www . sec . gov or on our website : www . AethlonMedical . com

TO ADDRESS U NMET NEEDS IN GLOBAL HEALTH & BIODEFENSE FOCUS

; 4 MISSION

FDA EXPEDITED ACCESS PATHWAY PROGRAM SUBMISSION 6

THE UNITED STATES FOOD AND DRUG ADMINISTRATION (FDA) HAS DESIGNATED THE AETHLON HEMOPURIFIER ® TO THE EXPEDITED ACCESS PATHWAY (EAP) PROGRAM RELATED TO THE TREATMENT OF LIFE - THREATENING VIRUSES THAT ARE NOT ADDRESSED WITH AN APPROVED THERAPY

INFECTIOUS HUMAN VIRUSES A SIGNIFICANT UNMET NEED IN GLOBAL HEALTH & BIODEFENSE &HQWHU IRU ;,PPXQLW\DQG(YROXWLRQ 8QLYHUVLW\RI(GLQEXUJK 8

9 A SIGNIFICANT UNMET NEED IN GLOBAL HEALTH & BIODEFENSE

+ (02385,),(5 $775,%87(6 5 (7+,1.,1* 7+( 75($70(17 2) 9,5$/ 3$7+2*(16 6 758&785( 63(&,),& 127 ',6($6( 63(&,),& 0(&+$1,60 2) $&7,21 * /<&$1 6+,(/' 7+( ,0081( &/2$. &$3785( 0(&+$1,60 ( /,0,1$7(6 +,*+/< */<&26</$7(' 9,586(6 )520 7+( (17,5( &,5&8/$725< 6<67(0 & 203$1,21 $66$< 5(,1)25&(6 0(&+$1,60 3(5)250$1&( ' (3/2<(' 21 $1 (67$%/,6+(' */2%$/ ,167580(17 1(7:25. 10 ,PDJHRI+,9JO\FDQVKLHOGLQJUHHQ &RXUWHV\RI2[IRUG8QLYHUVLW\

THE AETHLON HEMOPURIFIER FROM THEORETICAL CONCEPT TO CLINICAL REALITY ! ,1 9,752 9,586 &$3785(678',(6 ր ) 285 ,19(67,*$7,21$/ +80$1 678',(6 2876,'( 86 5(&(17/< &21&/8'(' $1 )'$ $33529(' + 80$1 ) ($6,%,/,7< 678'< ր 5(&(,9(' ( ;3(',7(' $ &&(66 3 $7+:$< ($3 '(6,*1$7(' )520 7+( )'$ 11

GOAL OF OUR EAP PROGRAM SUBMISSION

HEMOPURIFIER ® CAPTURE VALIDATIONS OF HIGHLY GLYCOSYLATED VIRUSES ŗŚ

Hemopurifier in vitro capture validations Bioterror & Pandemic Threat Viruses (EROD &'& 86$05,,' +XPDQ([SHULHQFH /DVVD 6RXWKZHVW)RXQGDWLRQIRU%LRPHGLFDO 5HVHDUFK 0(56 &R9 *RHWKH8QLYHUVLW\5HVHDUFK,QVWLWXWH 6PDOOSR[ %DWWHOOH0HPRULDO5HVHDUFK,QVWLWXWH EDVHGRQ0RQNH\SR[9DFFLQLDPRGHOV;

Hemopurifier® in vitro capture validations 0RVTXLWR %RUQH 9LUXVHV ր &KLNXQJXQ\D 1DWLRQDO,QVWLWXWHRI9LURORJ\ 'HQJXH 1DWLRQDO,QVWLWXWHRI9LURORJ\ :HVW1LOH %DWWHOOH0HPRULDO5HVHDUFK,QVWLWXWH =LND $HWKORQ5HVHDUFK7HDP 16

+HPRSXULILHULQYLWURFDSWXUHYDOLGDWLRQV 3DQGHPLF ,QIOXHQ]D9LUXVHV + 1 6ZLQH)OX $HWKORQ5HVHDUFK7HDP; + 1 %LUG)OX %DWWHOOH0HPRULDO5HVHDUFK,QVWLWXWH 6SDQLVK)OXRI 5 %DWWHOOH05 $FWXDO6SDQLVK)OXRI SDQGHPLFUHVXOWHGLQDSSUR[LPDWHO\ PLOOLRQ GHDWKVZRUOGZLGH

Hemopurifier in vitro capture validations &KURQLF /DWHQW 9LUXVHV ր +XPDQ,PPXQRGHILFLHQF\9LUXV $HWKORQ 5HVHDUFK7HDP +XPDQ7UHDWPHQW2XWFRPHV +HSDWLWLV&9LUXV $HWKORQ5HVHDUFK7HDP +XPDQ 7UHDWPHQW2XWFRPHV &\WRPHJDORYLUXV '2' '$53$ (SVWHLQ %DUU9LUXV '2' '$53$ +HUSHV6LPSOH[9LUXV '2' '$53$ 18

d ,; dZ Ed K& K s/Zh^ ^dhz' /E^d >/&; d,Z d E/E' ,/',>z '>z K^z>d s/Zh^ t/d,Khd E WWZKs d,;Z Wz

d , dZ dD Ed K& K s/Zh^ A SINGLE 6 . 5 - HOUR ADMINISTRATION OF H EMOPURIFIER ® THERAPY WAS DELIVERED TO THE PATIENT , WHO WAS COMATOSE WITH MULTIPLE ORGAN FAILURE . ŘŖ

THE TREATMENT OF EBOLA VIRUS

VIRUS CAPTURE ASSAY RESULT

Extracorporeal Virus Elimination for the Treatment of Severe Ebola Virus Disease - First Experience with Lectin Affinity Plasmapheresis Büttner S. a · Koch B. a · Dolnik O. b · Eickmann M. b · Freiwald T. a · Rudolf S. a · Engel J. a · Becker S. b · Ronco C. c · Geiger H. a Author affiliations Corresponding Author Keywords: Ebola virusGlycoproteinLectin affinityPlasmapheresis February 2015 Abstract Therapeutic options for Ebola virus disease (EVD) are currently limited to ( 1 ) best supportive care, and ( 2 ) evolving virus - specific therapies, resulting from decades of analyzing one of the world's deadliest diseases . Supportive care ranges from oral or intravenous rehydration therapy and anti - emetics in developing countries to much more extensive life - support interventions in resource - rich countries . Current EVD - specific therapies attempt to either interfere with the earliest steps of viral replication or to elicit a strong immune response against the virus . An entirely new approach is the extracorporeal elimination of viruses and viral glycoproteins by lectin affinity plasmapheresis . Herein, we report for the first time the successful and safe use of lectin affinity plasmapheresis in a patient with severe Ebola virus disease .

A SIGNIFICANT UNMET NEED IN GLOBAL HEALTH & BIODEFENSE

THE AETHLON HEMOPURIFIER ALIGNS TO MEET 5 DIFFERENT PHEMCE OBJECTIVES

LEVERAGE EAP PATHWAY DESIGNATION TO ESTABLISH COMMERCIALIZATION PATHWAY FOR VIRUSES THAT ARE ; LIFE - THREATENING • HIGHLY - GLYCOSYLATED NOT ADDRESSED WITH AN APPROVED THERAPY • AND , HAVE BEEN VALIDATED TO BE CAPTURED BY THE AETHLON HEMOPURIFIER

Focused on diagnosing diseases that are current or future therapeutic targets for Aethlon Medical